{
    "clinical_study": {
        "@rank": "85784", 
        "arm_group": [
            {
                "arm_group_label": "Arm I (no intervention)", 
                "arm_group_type": "No Intervention", 
                "description": "Patients receive no additional reminders."
            }, 
            {
                "arm_group_label": "Arm II (email survey)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive a reminder email survey every 2 weeks for 1 year after completing radiation."
            }, 
            {
                "arm_group_label": "Arm III (email surveys and phone calls)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive a reminder email survey as in Arm I and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized, pilot phase I trial studies whether phone or email reminders increases\n      vaginal dilator use in patients with endometrial, cervical, or vaginal cancers after they\n      undergo brachytherapy. Brachytherapy is a type of internal radiation which uses radioactive\n      material placed directly into or near a tumor to kill tumor cells. A reminder program may\n      help increase use of vaginal dilators and decrease long-term side effects following\n      brachytherapy."
        }, 
        "brief_title": "Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy", 
        "condition": [
            "Cervical Cancer", 
            "Endometrial Cancer", 
            "Radiation Toxicity", 
            "Vaginal Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Endometrial Neoplasms", 
                "Uterine Cervical Neoplasms", 
                "Vaginal Neoplasms", 
                "Radiation Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. Evaluate whether vaginal dilator adherence is improved with additional reminder phone\n      calls and/or email reminder survey.\n\n      SECONDARY OBJECTIVES:\n\n      I. Evaluate whether there are differences in the length of vaginal canal between the\n      non-intervention and intervention groups. Evaluate rates of gynecologic, urinary, and\n      gastrointestinal toxicity.\n\n      OUTLINE: Patients are randomized to 1 of 3 arms.\n\n      ARM I: Patients receive no additional reminders.\n\n      ARM II: Patients receive a reminder email survey every 2 weeks for 1 year after completing\n      radiation.\n\n      ARM III: Patients receive a reminder email survey as in Arm I and 4 additional phone calls\n      at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.\n\n      After completion of study, patients are followed up at 10-14 weeks, 5-7 months, 8-10 months,\n      11-13 months, 15-17 months, 19-21 months, and 23-25 months post treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with gynecologic cancer who are undergoing vaginal brachytherapy as part of\n             their treatment\n\n          -  Patients cannot have previously received pelvic external beam radiation or\n             brachytherapy\n\n          -  Patients should have a life expectancy of at least 1 year\n\n          -  No Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status\n             requirements\n\n          -  No organ and marrow function requirements\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  Patients who have received prior pelvic external beam radiation or brachytherapy will\n             be excluded\n\n          -  No restrictions regarding use of other investigational agents\n\n          -  No exclusion requirements due to co-morbid disease or intercurrent illness\n\n          -  No investigational agent, so no exclusion requirements regarding history of allergic\n             reactions attributed to compounds of similar chemical or biologic composition to\n             investigational agent or device\n\n          -  No exclusion criteria relating to concomitant medications\n\n          -  No exclusion criteria for pregnant or nursing patients from participating in this\n             study (Of note, pregnant patients will not be treated with vaginal brachytherapy, a\n             requirement for enrolling on this study)"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02058550", 
            "org_study_id": "GYN0005", 
            "secondary_id": [
                "NCI-2013-02400", 
                "29074", 
                "P30CA124435"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm II (email survey)", 
                    "Arm III (email surveys and phone calls)"
                ], 
                "description": "Receive reminder email survey", 
                "intervention_name": "survey administration", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Arm II (email survey)", 
                    "Arm III (email surveys and phone calls)"
                ], 
                "description": "Receive reminder email survey", 
                "intervention_name": "computer-assisted intervention", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Arm III (email surveys and phone calls)", 
                "description": "Receive reminder phone call", 
                "intervention_name": "telephone-based intervention", 
                "intervention_type": "Behavioral"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 6, 2014", 
        "location": {
            "contact": {
                "email": "jwynne@stanford.edu", 
                "last_name": "Jacob Wynne", 
                "phone": "650-723-8843"
            }, 
            "facility": {
                "address": {
                    "city": "Stanford", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94305"
                }, 
                "name": "Stanford University Hospitals and Clinics"
            }, 
            "investigator": {
                "last_name": "Elizabeth A. Kidd", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase I Pilot Study Evaluating Vaginal Dilator Use and Toxicity Following Vaginal Brachytherapy", 
        "overall_official": {
            "affiliation": "Stanford University Hospitals and Clinics", 
            "last_name": "Elizabeth Kidd", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The vaginal dilator adherence measurements will analyzed in repeated measures model with treatment as a fixed effect and time as a within subject effect. The overall mean of vaginal dilator adherence among the 3 groups will also be measured and compared. The interaction between treatment and time will also be tested to see if the behavior over time is different depending on which treatment arm the patient is in.", 
            "measure": "Vaginal dilator adherence, measured by the average number of times per week patient uses a form of vaginal dilation", 
            "safety_issue": "No", 
            "time_frame": "Up to 25 months after completing radiation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02058550"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The vaginal canal length will be measured using an extra small dilator and it will be calculated in centimeters. The vaginal canal length measurements will be analyzed in a repeated measures model with treatment as a fixed effect and time as a within subject effect. The interaction between treatment and time will also be tested to see if the behavior over time is different depending on which treatment arm the patient is in.", 
                "measure": "Vaginal canal length", 
                "safety_issue": "No", 
                "time_frame": "Up to 25 months after completing radiation"
            }, 
            {
                "description": "The adverse events will be tabulated by type and grade at each follow up. The total number of AE's as well as the number of AE's in each category: gynecologic, urinary and gastrointestinal will tabulated. The test of proportion will be done per category of AE. Since it is possible that the rates will be low, an exact test will be used to compare the rates.", 
                "measure": "Incidence of adverse events (AE), reported by type and grade using the Common Terminology Criteria for Adverse Events version 4.03", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days after the last dose of study treatment"
            }
        ], 
        "source": "Stanford University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2015", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}